Tumor-stroma ratio is associated with Miller-Payne and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer

Background: The tumor-stroma ratio (TSR) has proven to be a strong prognostic factor in breast cancer, demonstrating better survival for patients with stroma-low tumors. Since the role of TSR as a predictive marker for neoadjuvant chemotherapy outcome is yet unknown, this association was evaluated for HER2-negative breast cancer in the prospective DIRECT and NEOZOTAC trials.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: S. Hagenaars, S. de Groot, D. Cohen, A. Charehbili, T. Dekker, E.Meershoek-Klein Kranenbarg, M. Duijm-de Carpentier, H. Pijl, H. Putter, R. Tollenaar, J. Kroep, W. Mesker, Dutch Breast Cancer Research Group (BOOG) Tags: POSTERS B: Basic Science and Translational Research Source Type: research